Concord Drugs shares soar 4% after pharma order worth ₹14.71 CrConcord Drugs shares soar 4% after pharma order worth ₹14.71 Cr

Introduction

Leading pharmaceutical manufacturer secures ₹14.71 crore government orders for supply of various medicines to Tamil Nadu, Telangana, and central health departments, with execution scheduled within 45 to 60 days.

Also Read: Cupid Ltd to set up of FMCG manufacturing hub in Saudi Arabia, stock up 3%

Share price movement of Concord Drugs

On December 30, 2025, Concord Drugs Ltd opened at ₹80.32, down 3.34% from its previous close of ₹83.11. The stock reached a high of ₹86.40 (3.94%) and a low of ₹80.32 (–3.34%). By 3:40 PM, it traded at ₹86.00, a 3.48% increase, with a market cap of ₹86.00 crore.

Concord Drugs Secures ₹14.71 Crore Orders

Concord Drugs Limited has received significant purchase orders from multiple government entities during December 2025. The total value of the orders is approximately ₹14.71 crore, exceeding the materiality threshold.

The orders include supply to Tamil Nadu Medical Services Corporation Ltd, Directorate General of Health Services, and Telangana State Infrastructure Medical Services & Development Corporation. The contracts cover various pharmaceutical products.

The execution period for these orders is set between 45 and 60 days. All orders are domestic, and the contracts are expected to positively impact the business and operations of the company.

Stock performance of Concord Drugs for Period of 1 week, 6 months, and 1 year

Concord Drugs Ltd delivered a 0.18% return over the past week, it gained 56.0% in the past six months. The stock rose 129% over the past year.

Also Read: RVNL: Stock jumps after bagging order from the East Coast Railways to set up wagon workshops

Shareholding pattern of Concord Drugs

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	54.40%	54.40%	54.40%
FII	0.00%	0.00%	0.00%
DII	0%	0%	0%
Public	45.60%	45.60%	45.60%

About Concord Drugs

Concord Drugs Ltd (BSE: 538965), incorporated in 1995, manufactures licensed drugs. Its portfolio includes pellets, MUPS, tissue bio adhesives, injectables, oral solids, liquid orals, and dry syrup formulations for diverse pharmaceutical needs.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs